IPO Pipeline Reopens for H2 as Liquidity Tests Loom Larger

The IPO market’s second-half sprint is now underway, and the early read is that investors are picking selectively rather than buying the whole shelf. Scribe Therapeutics (Nasdaq: SCTX), a CRISPR gene-editing company co-founded by Jennifer Doudna, priced an upsized $129 million offering on July 23 at $15 per share and traded up roughly 44% in early sessions^[1]. Endpoints News described the deal as the start of a “second-half IPO spree” for biotech^[2]. At the other end of the quality spectrum, QumulusAI (QMLS) and Standard Nuclear (STDN), both priced in mid-July, are each down more than 44% from offer^[1]. The message from the tape is clear: the window is open, but it is not open equally for everyone.

This comes after a first half that absorbed record-setting supply. SpaceX (SPCX) raised $75 billion in June – the largest IPO in history – priced at $135, briefly traded to $225, and has since fallen below its offer price to around $115-120, down roughly 15% from IPO and nearly 49% from peak^[3][1]. SK hynix (SKHY) raised $26.5 billion on Nasdaq in early July, the largest foreign IPO in U.S. history, pricing ADRs at $149 and opening at $170, a 14% first-day pop^[4]. The deal now sits modestly above offer at $154.57, up 3.7%^[1].

The H2 pipeline fills fast – and globally

The deal calendar is not slowing. CXMT Corp., China’s largest DRAM maker, is set to debut on Shanghai’s STAR Market on July 27 after raising 57.92 billion yuan (approximately $8.6 billion), making it Asia’s largest IPO of 2026^[5]. Institutional demand exceeded 500 times the shares on offer. The post-listing valuation lands near $85 billion, and the company reported nearly $7.5 billion in Q1 revenue, a 700% year-over-year jump, having crossed into profitability for the first time^[5].

Back in the U.S., the mid-July cohort illustrates the bifurcation. Csquare (CSQR), a technology offering that raised $1.05 billion, is up 8.4% from its $21 offer price^[1]. But the smaller, less-established issuers are struggling: QumulusAI is down 45% and Standard Nuclear down 45% from offer, each in less than two weeks of trading^[1]. This split is historically normal for a reopening IPO market – the base rate is that quality and scale command a premium while speculative micro-cap deals get punished.

*CXMT priced at 8.66 yuan per share on the Shanghai STAR Market.

Sources: Renaissance Capital^[1], company announcements, crypto briefing^[5].

SpaceX: the structural stress test

SpaceX is becoming the market’s most-watched laboratory for post-IPO flow mechanics. The stock has been added to the Nasdaq-100 even as it continues to slide, tightening the link between SPCX and passive index flows at a moment of elevated volatility^[6]. Short interest has built to roughly $25 billion, with short sellers sitting on an estimated $15.5 billion in gains as the stock trades below its IPO price^[3].

The next two catalysts are tightly clustered: SpaceX’s first earnings report on August 4, followed by initial insider lock-up expirations on August 6^[6]. One report cited 911.5 million shares set to unlock^[3]. The combination of a thin public float, a looming supply overhang, and a fundamental event in the same week is the kind of setup that tests whether passive index-buying can absorb insider selling – or whether it amplifies the move instead.

What would have to be true for the bull case here? Starlink’s commercial traction would need to translate into near-term revenue visibility, and the August 4 print would need to demonstrate a credible path to narrowing losses. The bear case requires only that the lockup mechanically overwhelms demand at these levels, with the Nasdaq-100 inclusion creating a feedback loop: index trackers are forced buyers at the same time insiders are natural sellers. Both are plausible, and the spread between them – fair value estimates ranging from under $1 to nearly $239^[6] – reflects how wide the uncertainty actually is.

The plumbing has changed

Citadel Securities’ Scott Rubner published his 21st semiannual Global Market Intelligence review on June 30, and his central claim is that “markets entering the second half of 2026 bear little resemblance to the markets investors navigated for most of the past two decades”^[7]. The defining story, he argues, is not a single macro event but “the structural transformation of equity markets” – concentration, passive flows, and systematic strategies have changed how prices are set^[8].

Rubner’s earlier May 18 note, titled “Flow Fragility,” warned that the equity market was vulnerable to a “potential flow-of-funds unwind” after the S&P 500 ran up roughly 17% from its March 30 low^[7]. His July 14 follow-up, “After the Reset,” argued that fundamentals were reasserting themselves following that correction^[7]. The thread running through these notes is that the same passive and systematic flows that powered the rally can reverse quickly, and the IPO supply hitting the market now is arriving into a structure that amplifies both directions.

This is not an abstract concern. The S&P 500 and Nasdaq Composite logged their second consecutive weekly declines in the week ending July 25^[9], and the 10-year Treasury yield touched 4.7%, its highest since January 2025^[9]. CNBC noted that the setup – crude oil rallying, bonds selling off, Big Tech under pressure – resembles the configuration that preceded a monthlong sell-off in March^[9].

Liquidity drain meets new supply

The Treasury market is simultaneously pulling liquidity out of the system. Michael Kramer of Mott Capital flagged a roughly $106 billion liquidity drain in the week of July 21-25: $56 billion in net new T-bill issuance on Tuesday, $37 billion on Thursday, and $13 billion in coupon settlement on Friday^[10]. He expects heavy T-bill issuance to persist until Labor Day, creating a sustained headwind for risk assets^[10].

The 30-year Treasury yield closed at 5.12%, and the 30-year TIPS real yield hit 2.93%, a new cycle high^[10]. Rising long-end yields globally – in the UK, Japan, and the U.S. – complicate the picture for new equity issuance because they raise the discount rate applied to future cash flows, particularly for growth-stage IPOs where profitability is distant.

Kramer’s more subtle point is about dispersion. The market has been highly dispersed in 2026, with stocks moving independently and implied correlations at low levels. If liquidity drains and index-level volatility rises, the expectation is that implied correlations increase and dispersion unwinds – meaning stocks start trading in unison rather than independently^[10]. For the IPO market, this matters: in a high-dispersion regime, investors can differentiate between a Scribe Therapeutics and a QumulusAI. In a low-dispersion, rising-correlation regime, the baby tends to get thrown out with the bathwater, and even quality new issues can get swept lower.

Buybacks: the quiet counterweight

While the IPO market adds supply, corporate buybacks continue to remove it – though the pace is steady rather than dramatic. In the past two weeks alone: RELX announced a GBP 150 million non-discretionary buyback program running through early September^[11], ING continued its EUR 1 billion program^[11], Equinor commenced a third 2026 tranche of up to $1.125 billion^[11], and Alimentation Couche-Tard renewed its share repurchase program^[11]. The buyback engine is still running, but these are mostly continuation programs rather than fresh, large authorizations. The net supply-demand balance between new IPO issuance and ongoing buybacks is a closer call than it was in Q1, when buybacks dwarfed new listings.

What to watch next

• July 27: CXMT debuts on Shanghai’s STAR Market. The 500x institutional oversubscription^[5] suggests strong initial demand, but the question for global markets is whether a successful Chinese mega-IPO draws capital away from U.S.-listed alternatives or signals broader risk appetite.
• August 4: SpaceX’s first earnings report as a public company^[6]. The print will establish a fundamental baseline for a stock that has traded on narrative and index flows rather than financials.
• August 6: SpaceX initial insider lock-up expirations^[6]. The volume of shares unlocking versus the float available to absorb them will be the market’s clearest real-time test of whether passive demand can offset insider selling.
• Treasury issuance calendar through Labor Day: Sustained heavy T-bill issuance is expected to continue draining liquidity^[10]. Watch the spread between dispersion and implied correlation: if it narrows, it signals that the high-dispersion regime that helped IPO investors differentiate is breaking down.
• Biotech IPO queue: Scribe’s success may embolden more CRISPR and gene-therapy companies to file^[2]. The pace of S-1 filings in August will indicate whether the window is genuinely widening or whether Scribe was simply a quality outlier.
• Rubner’s next note: His trajectory from “flow fragility” (May) to “after the reset” (July) suggests he is watching whether the post-correction rally is fundamentally grounded or flow-driven again. The answer has direct implications for whether new IPO supply can be absorbed.

The base-rate view is that IPO reopenings following a dry spell produce a wide dispersion of outcomes – some strong deals, some broken ones – and that the structural backdrop (liquidity, flows, correlation regime) determines how forgiving the market is toward the marginal deal. Right now, that backdrop is tightening. The pipeline is real, but so is the squeeze.